News

SPRIM Global Investments and William Taylor Nominees jointly led the funding round, which will support the conduct of a Phase I trial of RheumaGen’s lead candidate, RG0401. Anticipated

PVT401 is said to be the second autoimmune drug candidate from Parvus. Parvus is focused on developing peptide-major histocompatibility complex (pMHC) nanomedicine drugs. These assets can activate in

The decision is intended for individuals with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), as assessed by an FDA-approved test. This marks offering a new

The ‘fully human’, immunoglobulin G4 (IgG4) antibody is tailored to target Protein S, aiming to restore balance in blood clotting and potentially serves as a ‘universal haemostatic therapy’

This marks the first NMPA-approved monoclonal antibody that targets gastric tumour cells expressing the biomarker CLDN18.2. The approval offers a new, highly targeted treatment option for individuals particularly

This decision follows the positive outcomes from the multicentre, open-label Phase II TRUST-I trial. The single-arm trial was instrumental in assessing the therapy’s tolerability, efficiency, and safety in

This strategic move involves a total payment of $18m and terminates prior agreements with VBI, including future milestone and royalty obligations. Under the terms of the agreement, Brii

As per the deal, WuXi Bio will offer comprehensive discovery services, including antibody generation, spearhead detection, optimisation, and developability assessment. These services will be supported by WuXi’s single

The new indication specifically targets unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) expressing programmed death-ligand 1 (PD-L1). The approval for the